Sygnature Discovery, a leading drug discovery contract research organisation, has announced a strategic brand relaunch, including a new website, cementing its position as a global drug discovery partner.
The new identity highlights truly integrated approach and positions Sygnature Discovery as the only provider of its kind across Europe and North America.
For more than 20 years, Sygnature Discovery has built a strong reputation for delivering high quality candidates. Continued investment and strategic acquisitions have enabled the company to support customers across the full drug discovery process, from target identification to candidate nomination.
Uniquely positioned as the only contract research organisation offering full Design, Make, Test, Analyze (DMTA) capabilities under one roof in both North America and Europe, Sygnature is now targeting increased awareness and market share on a global scale.
Over recent years, Sygnature Discovery has integrated several complementary businesses, strengthening its scientific breadth, scale and geographic footprint. Today, its capabilities span bioscience, protein science & structural biology, synthetic & medicinal chemistry, computer-aided drug design, drug metabolism & pharmacokinetics, in vivo pharmacology, and form & formulation, all delivered through co-located, multidisciplinary teams.
“We’ve grown significantly in scale and capability over the past two decades,” said Dr. Simon Hirst, chief executive officer of Sygnature Discovery. “Biotech and pharma companies are facing volatile investment conditions, tighter timelines and rising costs. Our truly integrated approach is built around helping customers navigate that reality — whether they’re outsourcing a whole programme or need expert input in a single discipline.
“By bringing together multidisciplinary expertise in co-located teams, supported by AI and automation, we help customers move faster and improve the quality of their decisions. Across Europe and North America, we act as an extension of our customers’ teams, delivering a service they can trust.”
Sygnature Discovery, a global drug discovery contract research organisation, we create exceptional scientific outcomes. For our customers, who bring life-changing medicines to patients; and for our people, who help make this possible.
Sygnature Discovery through its dedicated contract research organisation services transform complex immunological questions into clear, actionable data that drives informed decision-making and accelerates your pre-clinical drug discovery programmes from concept to clinic.
Sygnature Discovery is providing expertise and innovative solutions to accelerate your immune-therapeutics into the clinic. Its tailored approach to assay design and execution provides precise solutions for novel therapeutics, ensuring the success of your drug development programme. The company’s contract research organisation services and collaborative efforts have helped our partners achieve quality outcomes to their immunology-focused enquiries.
The company hare 700 plus scientists from over 50 countries, working as one across Europe and North America. With no competing internal programs, we offer total confidentiality and commitment.
Over the past 20 years, we’ve earned a track record of real impact: 60 plus advanced candidates, 200 plus patents filed, 200 plus active projects. Over 90 per cent of our customers choose to stay with us from biotechs racing to clinic to pharmaceutical companies that need specialised expertise for targeted challenges.
Sygnature Discovery’s capabilities include medicinal chemistry, in vitro biology, computational chemistry and informatics, drug design, drug metabolism & pharmacokinetics, and protein crystallography. With a team of 400 pharmaceutical industry-experienced research scientists (over 80 per cent PhD qualified) Sygnature Discovery have a reputable track record of driving drug discovery projects towards the clinic. |